After successful bone marrow transplantation, patient hematopoietic and lymphoid cells are replaced by cells derived from the donor marrow. To document and characterize successful engraftment, host and donor cells must be distinguished from each other. We have used DNA sequence polymorphism analysis to determine reliably the host or donor origin of posttransplant cell populations. Using a selected panel of six cloned DNA probes and associated sequence polymorphisms, at least one marker capable of distinguishing between a patient and his sibling donor can be detected in over 95% of cases. Posttransplant patient peripheral leukocytes were examined by DNA restriction enzyme digestion and blot hybridization analysis. We have studied 18 patients at times varying from 13 to 1,365 d after marrow transplantation. Mixed lymphohematopoietic chimerism was detected in 3 patients, with full engraftment documented in 15. One patient with severe combined immunodeficiency syndrome was demonstrated to have T cells of purely donor origin, with granulocytes and B cells remaining of host origin. Posttransplant leukemic relapse was studied in one patient and shown to be of host origin. DNA analysis was of particular clinical value in three cases where failure of engraftment or graft loss was suspected. In two of the three cases, full engraftment was demonstrated and in the third mixed lymphohematopoietic chimerism was detected. DNA sequence polymorphism analysis provides a powerful tool for the documentation of engraftment after bone marrow transplantation, for the evaluation of posttransplant lymphoma or leukemic relapse, and for the comprehensive study of mixed hematopoietic and lymphoid chimeric states.
Introduction
have been used for this purpose include: erythrocyte antigen typing (2) (3) (4) (5) (6) , HLA-typing (6) , leukocyte isoenzymes (2) (3) (4) , immunoglobulin isotypes (4, 7), Barr and Y-body analysis (8) (9) (10) (11) (12) , and karyotyping techniques (3-6, 9, 11, 13-15) . Cytogenetic techniques are only rarely applicable where patient and donor are of the same sex. Furthermore, karyotype analysis requires cell division and thus is restricted to proliferating cell populations. Erythrocyte antigen and immunoglobulin isotype studies are obscured by transfusion and are rarely useful in the first few months after transplantation. In addition these latter techniques each provide information relevant to only one cell line. HLA-typing only applies when the patient and donor are not HLA-identical. Despite these limitations, occasional cases of mixed hematopoietic chimerism have been documented (3, 5, 11, 14, 16, 17) . Engraftment, however, is frequently determined based solely on the rise in peripheral blood counts at the expected time after marrow transplantation.
DNA sequence polymorphisms are neutral variations in DNA sequence present throughout the genome, which can often be detected by restriction enzyme digestion and blot hybridization analysis. Most well-described DNA sequence polymorphisms involve single nucleotide changes, or small insertions or deletions, which result in the presence or absence of a particular restriction enzyme recognition site (18) (19) (20) (21) . In another type of polymorphism, a large segment of DNA of unknown function varies widely in length among individuals (22, 23) . Both types of sequence differences and resulting varying DNA restriction fragment lengths are inherited in Mendelian fashion. The end result is a unique band pattern on blot hybridization analysis that can often clearly distinguish between two individuals.
An increasing number of such sequence polymorphisms have been described involving portions of several different chromosomes (18) (19) (20) (21) (22) (23) (24) . These genetic markers have been widely used in the study and prenatal diagnosis of the hemoglobinopathies (18, 19, 25, 26) , and more recently in the analysis of other disorders (19, 20, 23 Table I . Preparative chemoradiation therapy varied according to the underlying disease and is also outlined in Table  I . Donor selection, conditioning regimens, transplantation procedure, and posttransplant management have been previously described (1, 3, 6, 27 Hybridization with DNA probes. The panel of six probes and corresponding restriction enzymes used, the chromosomal localization, and the allelic frequencies are listed in Table II . For PGK, AT3, BIVS2, and El.3 purified insert was used as probe, whereas for PDP34 and PAW101 intact plasmid was used. The probes were labeled by nick translation with 32P-deoxynucleotide triphosphates (New England Nuclear, Boston, MA, or Amersham Corp., Arlington Heights, IL) to sp act 1 to 5 X 108 dpm/,ug of DNA. Nitrocellulose filters prepared as above were then hybridized with the appropriate 32P-labeled probe, washed, and examined by autoradiography as previously described (28) .
Fractionation of cells posttransplantation. At varying times after transplantation, 10 to 50 cm3 of patient blood were collected, defibrinated by agitation with glass beads, and, when sufficient cells were Table III .
General applicability and sensitivity. Given the various allelic frequencies listed in Table II Fig. 4.) phism maximally informative for patient was found in 17 of 18, and in all of these 17 the same, or a second probe was also maximally informative for donor (Table III) .
To assess the sensitivity of this technique, a mixing experiment was performed, in which patient and donor DNA were mixed in varying proportions keeping the total constant, and then examined by restriction enzyme digestion and blot hybridization as outlined above. The minor population was still visible at levels as low as 1% of total DNA (Fig. 2 ). An equivalent level of sensitivity has been attained by Cleary et al. (32) using similar techniques to evaluate immunoglobulin gene rearrangements in mixed lymphoid populations.
Clinical utility. 18 cases have been examined after transplantation and these results are shown in Table I (Fig. 4) (18) (19) (20) (21) (22) (23) (24) have facilitated the study of inherited disease (18-20, 25, 26) . We report here the use of polymorphism analysis to establish the origin of cells following bone marrow transplantation.
The capacity to detect the change of a patient's hematopoietic and lymphoid cell compartments from host to donor origin after bone marrow transplantation is clinically useful in assessing both the occurrence and completeness of engraftment.
The pattern of engraftment, particularly in the occasional case of mixed lympho-hematopoietic chimerism, is also of biologic interest and may add to our understanding of the mechanisms of graft rejection, GVHD, and the process of immune system reconstitution. The usual techniques used for this purpose show varying sensitivity and have been limited by the lack of general applicability to all patients and all cells in those patients. DNA sequence polymorphism analysis is applicable to over 95% of patients with the present panel of six probes, and with the addition of further probes could theoretically be applied to any patient/donor pair (excluding identical twins). Sensitivity is high, with small residual host (or donor) cell populations detectable at levels as low as 1% of the cells examined, which exceeds the purity of many cell fractionation techniques. Furthermore, any population of nucleated cells can be studied, regardless of mitotic phase.
Bone marrow transplantation performed following marrow ablative preparation with standard doses of TBI and high dose cyclophosphamide is generally followed by disappearance of all host lympho-hematopoietic elements and subsequent replacement by donor cells resulting in a "pure" chimeric state (1) Following nonablative transplant preparation for aplastic anemia, failure of engraftment with subsequent autologous recovery may occur (1, 16) , and mixed lympho-hematopoietic chimerism has been reported in a few cases (14, 16) . SCIDS patients receiving no marrow ablative preparation frequently become mixed chimeras with hematopoietic cells still of host origin, T cells of donor origin, and B cells variably of donor or host origin (17) . Mixed chimerism has also been encountered following transplantation for several other childhood immune disorders (3, 17) .
In our study, using a more sensitive technique and studying all peripheral blood nucleated cells, we detected evidence of mixed hematopoietic or lymphoid chimerism in only 1 (3, 11, 14, 16) .
In addition to the study of mixed lympho-hematopoietic chimerism, we have demonstrated the clinical value of DNA analysis in cases of questionable engraftment or graft rejection following bone marrow transplantation. We have also shown that this approach is useful in the study of recurrent leukemia following bone marrow transplantation for distinguishing relapse ofthe original host leukemia from a second leukemia originating in donor cells. Although few patients have relapsed in donor cells (9) , a more accurate assessment of the problem could be made by applying this technique to a larger number of cases. In addition to our case reported here, Minden and Messner have studied one case of recurrent leukemia also documenting host origin using DNA analysis (35) . Rare cases of lymphoma arising in patients after marrow transplant can be studied similarly to determine the donor or host origin of the tumor. (8, 10, 12) .
In summary, we used molecular genetic techniques to study the origin of cells after bone marrow transplantation. This approach, based on the analysis of DNA polymorphisms is widely applicable, highly sensitive, and can be used to study any population of nucleated cells. Applications include the documentation of marrow engraftment, the detection and study of mixed lympho-hematopoietic chimerism, and the evaluation of posttransplant leukemic relapse.
